NCT07483489

A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).

A Randomized，Double-Blind, Multicenter，Placebo-Controlled, Parallel-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of HW091077 in Participants With Refractory Chronic Cough or Unexplained Chronic Cough (RCC/UCC).

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC/UCC).

Conditions

• Refractory Chronic Cough

Interventions

Type	Name	Description
DRUG	HW091077	HW091077 oral tablet, oral, QD
DRUG	HW091077	HW091077 oral tablet, oral, QD
DRUG	Matching placebo to HW091077	Matching placebo to HW091077 oral tablet, oral, QD

Timeline

• Start date: 2026-05-01
• Primary completion: 2028-08-30
• Completion: 2028-08-30
• First posted: 2026-03-19
• Last updated: 2026-03-19